Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066) Presenter: Fiona Simpkins, M.D.
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / NEW YORK, February 27, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.